Questran Light is used for: 1. Primary prevention of coronary heart disease in men between 35 and 59 years of age and with primary hypercholesterolaemia who have not responded to diet and other appropriate measures. 2. Reduction of plasma cholesterol in hypercholesterolaemia, particularly in those patients who have been diagnosed as Fredrickson's Type II (high plasma cholesterol with normal or slightly elevated triglycerides). 3. Relief of pruritus associated with partial biliary obstruction and primary biliary cirrhosis. 4. Relief of diarrhoea associated with ileal resection, Crohn's disease, vagotomy and diabetic vagal neuropathy. 5. Management of radiation-induced diarrhoea.
Questran is used for: 1. Primary prevention of coronary heart disease in men between 35 and 59 years of age and with primary hypercholesterolaemia who have not responded to diet and other appropriate measures. 2. Reduction of plasma cholesterol in hypercholesterolaemia, particularly in those patients who have been diagnosed as Fredrickson's Type II (high plasma cholesterol with normal or slightly elevated triglycerides). 3. Relief of pruritus associated with partial biliary obstruction and primary biliary cirrhosis. 4. Relief of diarrhoea associated with ileal resection, Crohn's disease, vagotomyand diabetic vagal neuropathy. 5. Management of radiation-induced diarrhoea.
FDA approves the Light Adjustable Lens and Light Delivery Device for post cataract surgery.
Disease overview: Immunoglobulin light chain amyloidosis is a clonal, nonproliferative plasma cell disorder in which fragments of immunoglobulin light or heavy chain are deposited in tissues.
Systemic immunoglobulin light chain amyloidosis is a protein misfolding disease caused by the conversion of immunoglobulin light chains from their soluble functional states into highly organized amyloid fibrillar aggregates that lead to organ dysfunction.
Orexigen Therapeutics, Inc. announced successful results of the interim analysis of the LIGHT Study. Based on these results, the Company...
BioPhotas has announced it has received Over-The-Counter clearances by the FDA of the Celluma, its biophotonic medical light therapy device....
The LIGHT Study which the FDA had asked Orexigen not to disclose (but whose results were disclosed with a new...